Search Results

There are 20694 results for: content related to: Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

  1. You have free access to this content
    Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 8, August 2015, Pages: 1494–1502, S. Nylander, F. Wågberg, M. Andersson, T. Skärby and D. Gustafsson

    Version of Record online : 23 JUL 2015, DOI: 10.1111/jth.13027

  2. You have free access to this content
    Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a ‘shear’ delight!

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 10, October 2012, Pages: 2123–2126, S. P. JACKSON and S. M. SCHOENWAELDER

    Version of Record online : 1 OCT 2012, DOI: 10.1111/j.1538-7836.2012.04912.x

  3. You have free access to this content
    Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

    International Journal of Cancer

    Volume 125, Issue 10, 15 November 2009, Pages: 2332–2341, Kathryn Balmanno, Simon D. Chell, Annette S. Gillings, Shaista Hayat and Simon J. Cook

    Version of Record online : 28 MAY 2009, DOI: 10.1002/ijc.24604

  4. Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 1, January 2013, Pages: 35–41, M. Sjöstrand, H. Ericsson, M. Hartford, E. Norjavaara and J. W. Eriksson

    Version of Record online : 9 SEP 2012, DOI: 10.1111/j.1463-1326.2012.01672.x

  5. You have free access to this content
    Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

    British Journal of Haematology

    Volume 139, Issue 1, October 2007, Pages: 55–63, Iris Breitkreutz, Marc S. Raab, Sonia Vallet, Teru Hideshima, Noopur Raje, Dharminder Chauhan, Nikhil C. Munshi, Paul G. Richardson and Kenneth C. Anderson

    Version of Record online : 11 SEP 2007, DOI: 10.1111/j.1365-2141.2007.06747.x

  6. You have free access to this content
    AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma

    Cancer

    Volume 116, Issue 5, 1 March 2010, Pages: 1315–1325, Hung Huynh

    Version of Record online : 25 JAN 2010, DOI: 10.1002/cncr.24863

  7. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer

    The Prostate

    Volume 75, Issue 15, November 1, 2015, Pages: 1747–1759, Hongzoo Park, Yunlim Kim, Jee-Won Sul, In Gab Jeong, Hye-Jin Yi, Jae Beom Ahn, Jong Soon Kang, Jieun Yun, Jung Jin Hwang and Choung-Soo Kim

    Version of Record online : 7 AUG 2015, DOI: 10.1002/pros.23057

  8. You have free access to this content
    Blockade of MEK signaling potentiates 5-Aza-2′-deoxycytidine-induced apoptosis and upregulation of p21waf1 in acute myelogenous leukemia cells

    International Journal of Cancer

    Volume 125, Issue 5, 1 September 2009, Pages: 1168–1176, Chie Nishioka, Takayuki Ikezoe, Jing Yang, Naoki Komatsu, H. Phillip Koeffler and Akihito Yokoyama

    Version of Record online : 18 FEB 2009, DOI: 10.1002/ijc.24377

  9. Effects of a novel potent melanin-concentrating hormone receptor 1 antagonist, AZD1979, on body weight homeostasis in mice and dogs

    British Journal of Pharmacology

    Volume 173, Issue 18, September 2016, Pages: 2739–2751, Karolina Ploj, Lambertus Benthem, Dorota Kakol-Palm, Peter Gennemark, Liselotte Andersson, Mikael Bjursell, Jenny Börjesson, Lillevi Kärrberg, Marianne Månsson, Madeleine Antonsson, Anders Johansson, Suzanne Iverson, Björn Carlsson, Andrew Turnbull and Daniel Lindén

    Version of Record online : 3 AUG 2016, DOI: 10.1111/bph.13548

  10. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

    Annals of Neurology

    Volume 77, Issue 6, June 2015, Pages: 953–971, Adam C. Kaufman, Santiago V. Salazar, Laura T. Haas, Jinhee Yang, Mikhail A. Kostylev, Amanda T. Jeng, Sophie A. Robinson, Erik C. Gunther, Christopher H. van Dyck, Haakon B. Nygaard and Stephen M. Strittmatter

    Version of Record online : 21 MAR 2015, DOI: 10.1002/ana.24394

  11. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program

    Pediatric Blood & Cancer

    Volume 55, Issue 4, October 2010, Pages: 668–677, E. Anders Kolb, Richard Gorlick, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernan Carol, Richard Lock, Doris Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine Billups and Malcolm A. Smith

    Version of Record online : 24 MAY 2010, DOI: 10.1002/pbc.22576

  12. You have free access to this content
    Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells

    International Journal of Cancer

    Volume 140, Issue 1, 1 January 2017, Pages: 109–119, Hee-Jun Kim, Ahrum Min, Seock-Ah Im, Hyemin Jang, Kyung Hun Lee, Alan Lau, Miso Lee, Seongyeong Kim, Yaewon Yang, Jungeun Kim, Tae Yong Kim, Do-Youn Oh, Jeffrey Brown, Mark J. O'Connor and Yung-Jue Bang

    Version of Record online : 21 OCT 2016, DOI: 10.1002/ijc.30373

  13. The effects of the nonselective benzodiazepine lorazepam and the α23 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 2, March/April 2015, Pages: 149–154, Erik T. te Beek, Xia Chen, Gabriël E. Jacobs, Kimberly J. Nahon, Marieke L. de Kam, Jaakko Lappalainen, Alan J. Cross, Joop M. A. van Gerven and Justin L. Hay

    Version of Record online : 27 AUG 2014, DOI: 10.1002/cpdd.134

  14. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

    Molecular Carcinogenesis

    Volume 49, Issue 4, April 2010, Pages: 353–362, Young-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang and Tae-You Kim

    Version of Record online : 26 MAR 2010, DOI: 10.1002/mc.20607

  15. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma

    Veterinary and Comparative Oncology

    Volume 13, Issue 3, September 2015, Pages: 288–304, J. S. Fowles, C. L. Denton and D. L. Gustafson

    Version of Record online : 7 JUN 2013, DOI: 10.1111/vco.12044

  16. MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim

    Cell Biology International

    Volume 38, Issue 4, April 2014, Pages: 435–443, Xiao-Bin Lv, Xing Zhang, Lan Deng, Ling Jiang, Wei Meng, Zhigang Lu and Xiuju Wang

    Version of Record online : 12 FEB 2014, DOI: 10.1002/cbin.10225

  17. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 12, December 2012, Pages: 1114–1122, L. A. Morrow, M. Leonsson-Zachrisson, H. Ericsson, M. Wollbratt, M. Knutsson, M. Hompesch and E. Norjavaara

    Version of Record online : 31 JUL 2012, DOI: 10.1111/j.1463-1326.2012.01661.x

  18. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 2, February 2013, Pages: 136–143, H. Denison, C. Nilsson, M. Kujacic, L. Löfgren, C. Karlsson, M. Knutsson and J. W. Eriksson

    Version of Record online : 30 SEP 2012, DOI: 10.1111/dom.12002

  19. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial

    International Journal of Clinical Practice

    Volume 63, Issue 4, April 2009, Pages: 667–670, S. Husted, R. A. Harrington, C. P. Cannon, R. F. Storey, P. Mitchell and H. Emanuelsson

    Version of Record online : 16 MAR 2009, DOI: 10.1111/j.1742-1241.2009.02030.x

  20. You have free access to this content
    Anticipating drug resistance in the MAP kinase pathway

    Pigment Cell & Melanoma Research

    Volume 23, Issue 1, February 2010, Pages: 7–9, Ronen Marmorstein

    Version of Record online : 2 DEC 2009, DOI: 10.1111/j.1755-148X.2009.00657.x